latest news releases from the newsroom
Assure Energy, Inc.
Assure Increases Daily Production Over 300% in a Year
CALGARY, Alberta, May 14, 2004 (PRIMEZONE) -- Assure Energy, Inc. (Assure) (OTCBB:ASURF) (Frankfurt WKN 357954 Symbol ASL) is pleased to announce that Assure, through its subsidiaries, Assure Oil & Gas Corp. (Assure O & G) and Westerra 2000 Inc. (Westerra) and 48.5 % controlled Quarry Oil & Gas Ltd. (Quarry) (TSX-v: QUC) has completed its Fall-Winter 2003/04 Multi Well Drilling Program in Canada's Western Sedimentary Basin resulting in Assure raising its production of oil or its natural gas equivalents per day (boe/d) (at 6:1 ratio) to approximately 1415 boe/d on a consolidated basis. This amounts to over a 300% increase in daily production from the end of last years winter drilling season to the end of the 2004 winter drilling season for Assure on a consolidated basis.
Millennium Chemicals Reports First Quarter Operating Results and Schedules Internet Webcast/Teleconference
HUNT VALLEY, Md., May 14, 2004 (PRIMEZONE) -- Millennium Chemicals (NYSE:MCH) ("Millennium" or the "Company") today reported a net loss for the first quarter of 2004 of $10 million or $0.16 per common share. For the corresponding quarter of 2003, Millennium reported a net loss of $27 million or $0.43 per common share. Excluding designated items(1), the first quarter 2004 net loss was $3 million or $0.05 per common share compared to a loss of $23 million or $0.36 per common share for the corresponding quarter of 2003.(2)
Abbey Spanier Rodd & Abrams, LLP
Abbey Gardy, LLP Commences Class Action Securities Fraud Suit Against NYFIX, Inc. and Certain Of Its Officers and Directors -- NYFXE
NEW YORK, May 14, 2004 (PRIMEZONE) -- Abbey Gardy, LLP commenced a Class Action lawsuit in the United States District Court for the District of Connecticut (04 CV 802) on behalf of all purchasers of securities of NYFIX, Inc. ("NYFIX" or the "Company") (Nasdaq:NYFXE) between March 30, 2000 and March 30, 2004, inclusive (the "Class Period").
HepaLife Technologies, Inc.
HepaLife Expands into Developing Technology for Hepatotoxicity, the Most Common Reason Cited for the Withdrawal of an Approved Drug, Pre-Clinical Drug Failures, and for Refusal of Drug Approval by the FDA
VANCOUVER, B.C., May 14, 2004 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF), a development stage biotechnology company focused on technologies and products to treat various forms of liver dysfunction and disease, is pleased to announce its plans for the development of liver cell specific in vitro toxicology and pre-clinical drug testing platforms. The in vitro platforms will be based on the patented PICM-19 pig liver stem cell line which is currently being tested by the Company for use in an artificial liver device.
PharmChem Reports First Quarter 2004 Results
HALTOM CITY, Texas, May 14, 2004 (PRIMEZONE) -- PharmChem, Inc. (Pink Sheets:PCHM) announced that its net sales for the first quarter ended March 31, 2004 were $5,606,000, a decrease of 11.5% from first quarter 2003 net sales of $6,335,000. The Company reported a loss for the current quarter of $628,000, or $0.11 per share, versus a loss of $733,000, or $0.13 per share, a year ago.